FDA accepts Seattle Genetics' lymphoma drug Adcetris for review

05/16/2013 | Bloomberg Businessweek · PharmaTimes (U.K.)

The FDA has accepted Seattle Genetics' supplemental biologics license application for the use of Adcetris, or brentuximab vedotin, for retreatment and use beyond 16 cycles of therapy in patients with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A decision is expected by Sept. 14.

View Full Article in:

Bloomberg Businessweek · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide